Literature DB >> 6146666

Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands.

M R Lalloz, P G Byfield, R M Greenwood, R L Himsworth.   

Abstract

Amiodarone is chiefly bound to albumin (62.1%) and much of the remainder (33.5%) is carried on a high molecular weight protein, probably beta-lipoprotein. Analysis of data for amiodarone binding to albumin revealed a high affinity primary binding site (Ka 5.6 X 10(6) litre mol-1) with about four secondary sites (average Ka 1.9 X 10(5) litre mol-1). Studies of the binding of amiodarone in serum revealed one type of binding site only with an affinity constant (Ka 4.2 X 10(6) litre mol-1) similar to that of the primary site on albumin. The secondary albumin binding sites do not seem therefore to be utilized in whole serum and the affinity of the lipoprotein must be similar to that of the primary amiodarone binding site on albumin. The effects of a wide range of compounds on albumin binding of amiodarone were examined by equilibrium dialysis. Quinidine, amitriptyline, cephazolin and palmitate decreased albumin-bound [125I]amiodarone. Neither warfarin nor digoxin affected the binding of amiodarone by albumin, thus of the three drugs known to be potentiated by concomitant amiodarone administration, only potentiation of quinidine could be explained by displacement from serum albumin. Rifampicin, frusemide, phenytoin, (-)-adrenaline, bromocresol green, (-)-noradrenaline and bromocresol purple were found to increase binding of [125I]amiodarone by albumin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6146666     DOI: 10.1111/j.2042-7158.1984.tb04400.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  15 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

3.  The influence of hyperlipoproteinemia on in vitro distribution of amiodarone and desethylamiodarone in human and rat plasma.

Authors:  Anooshirvan Shayeganpour; Stephen D Lee; Kishor M Wasan; Dion R Brocks
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

4.  The potentiation of acenocoumarol anticoagulant effect by amiodarone.

Authors:  M Arboix; M E Frati; J R Laporte
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

Review 5.  Pharmacokinetic drug interactions with amiodarone.

Authors:  L J Lesko
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

6.  Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions.

Authors:  K Ohyama; M Nakajima; M Suzuki; N Shimada; H Yamazaki; T Yokoi
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

7.  Antioxidant activity of amiodarone on human lipoprotein oxidation.

Authors:  D Lapenna; G Ciofani; C Bruno; S D Pierdomenico; F Cuccurullo
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

8.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.

Authors:  M E Veronese; S McLean; R Hendriks
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

9.  Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver.

Authors:  Takaaki Kodawara; Satohiro Masuda; Hiroko Wakasugi; Yuichi Uwai; Takahiro Futami; Hideyuki Saito; Takaaki Abe; Ken-ichi Inu
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 10.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.